MHRA approves teplizumab to delay progression of type 1 diabetes
مراجعة من قبل الدكتور كولين تايدي، MRCGPAuthored by Lawrence Higginsنُشر في الأصل 20 Aug 2025
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- نسخة صوتية
- Add to preferred sources on Google
Teplizumab (Tzield) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to help delay the onset of Stage 3 type 1 diabetes (T1D).
Read on to see what this means if you are prescribed teplizumab and what it does for you.
اشترك في دورة السكري المجانية لمدة 10 أسابيع!
كل أسبوع، سنستكشف موضوعًا مختلفًا لمساعدتك على فهم وإدارة مرض السكري بشكل أفضل، بما في ذلك الحياة اليومية والأدوية، والصحة النفسية، وآخر التطورات في تكنولوجيا السكري، والتغذية.
By subscribing you accept our سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.
في هذه المقالة:
تابع القراءة أدناه
What is teplizumab?
Teplizumab is the UK’s first-ever approved medicine that can be used treat type 1 diabetes using immunotherapy - which activates or suppresses the body’s immune system. Teplizumab has been approved for by MHRA for people with Stage 2 T1D, which is an earlier stage where people are at high risk of progressing to Stage 3 T1D.
The medicine can delay the onset of Stage 3 T1D by an average of three years in adults and children aged 8 years and older, who already have Stage 2 T1D.
Teplizumab is taken directly into your blood stream (intravenous infusion), usually through a drip, once a day, for 14 days.
Dr Elizabeth Robertson, Director of Research and Clinical at Diabetes UK, says: “Licensing teplizumab in the UK marks a turning point in the treatment of type 1 diabetes. For the first time, we have a medicine that targets the root cause of the condition, offering up to three precious extra years from the relentless demands of managing type 1 diabetes.”
When is Stage 3 T1D diagnosed?
You are usually diagnosed with Stage 3 T1D when you begin to have blood sugar problems which often require lifelong insulin treatment.
Are there side effects of teplizumab?
العودة إلى المحتوياتTeplizumab has been approved through the International Recognition Procedure (IRP), whose expertise the MHRA can use to benefit people in the UK. A full list of side effects will be published before teplizumab is made available.
As with any medicine, the MHRA will keep monitoring the safety and effectiveness of teplizumab.
If you think you are having a side effect from this medicine speak to your doctor, pharmacist, or nurse. You should also report it directly to the MHRA Yellow Card scheme.
Will teplizumab be avaiable on the NHS?
Whilst the MHRA has approved teplizumab, the National Institute for Health and Care Excellence (NICE), the body which approves the prescribing of medicines by the NHS, is still assessing if teplizumab should be available to the public.
In May 2025, NICE said it would not be able to recommend teplizumab because more evidence was needed. NICE’s updated guidance is expected in late November 2025.
Robertson says: “To ensure teplizumab reaches everyone who could benefit, we need it to be made available on the NHS, and the rollout of a screening programme to identify those with early-stage type 1 diabetes.”
Patient picks for Type 1 diabetes
السكري
Continuous glucose monitoring in type 1 diabetes
Type 1 and type 2 diabetes are both potentially serious conditions which should always be taken seriously. They’re both diagnosed on the basis of high blood sugar. But in other respects they are very, very different. Type 2 is largely down to lifestyle – getting type 1 is absolutely nothing to do with whether you eat too much sugar, carry excess weight or don’t exercise enough. People with type 2 diabetes often never need insulin – those with type 1 need it from day one. Many people with type 2 diabetes never need treatment that carries a risk of disabling low blood sugar (hypoglycaemia) – people with type 1 live with this risk every day. As a result, many people with type 2 never need to check their blood sugar several times a day – for people with type 1, it’s a highly unwelcome occupational hazard.
بقلم الدكتورة سارة جارفيس MBE، FRCGP
السكري
What is diabulimia?
When our children are tiny, we sometimes feel helpless - perhaps at 4 am when they're crying inconsolably or have been coughing for hours. Yet at least we know exactly what's going on, because we're in charge of every aspect of their lives. How much harder it is when our children are no longer entirely dependent and we have to rely on them to make the right choices.
بقلم الدكتورة سارة جارفيس MBE، FRCGP
اشترك في دورة السكري المجانية لمدة 10 أسابيع!
كل أسبوع، سنستكشف موضوعًا مختلفًا لمساعدتك على فهم وإدارة مرض السكري بشكل أفضل، بما في ذلك الحياة اليومية والأدوية، والصحة النفسية، وآخر التطورات في تكنولوجيا السكري، والتغذية.
By subscribing you accept our سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.
تاريخ المقال
تمت مراجعة المعلومات الموجودة في هذه الصفحة من قبل أطباء مؤهلين.
المراجعة التالية مستحقة: 20 أغسطس 2028
20 Aug 2025 | نُشر في الأصل
كتبه:
لورانس هيغينزمراجعة من قبل
الدكتور كولين تايدي، MRCGP
اسأل، شارك، تواصل.
تصفح المناقشات، اطرح الأسئلة، وشارك التجارب عبر مئات المواضيع الصحية.
هل تشعر بتوعك؟
قم بتقييم أعراضك عبر الإنترنت مجانًا
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
By subscribing you accept our سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.